Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Operating

Expenses:

Research and

development 7,537 8,200 21,404 23,989 113,867

General and

administrative 3,954 4,371 9,994 14,676 52,745

Impairment of

leasehold

improvements - - - - 1,030

Depreciation and

amortization 315 382 924 1,036 3,829

In-process

research and

development - - - - 418

Total

operating

expenses 11,806 12,953 32,322 39,701 171,889

Loss from

operations (11,806) (9,300) (32,322) (29,079) (159,485)

Other income

(expenses):

Interest

income 1,593 1,019 3,346 4,053 11,993

Interest

expense (90) (49) (269) (179) (1,608)

Change in

fair value

of warrant

liability - - (149) - (454)

Other expense - - - - (1,180)

Loss before

tax benefit (10,303) (8,330) (29,394) (25,205) (150,734)

(Provision

for)/benefit

from income

taxes - 150 - - 695

Net loss (10,303) (8,180) (29,394) (25,205) (150,039)

Deemed

dividend - - - - (19,424)

Preferred

stock

accretion - - (351) - (802)

Net loss

attributable

to common

stockholders $(10,303) $(8,180) $(29,745) $(25,205) $(170,265)

Net loss

attributable

to common

stockholders

per common

share - basic

and di
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... --  Pharnext SAS today announced that data related to ... Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four posters ... (PNS) Biennial Meeting at the Quebec Congress Center in ... 2, 2015. At Poster Viewing Session 4, four ... 7p.m. EDT: Poster 23: "A Meta-Analysis Of ...
(Date:6/29/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... patent-protected processes to develop and market advanced products and ... Medicine, Ophthalmic and Dental sectors of healthcare, announced that ... been awarded the Lifetime Achievement Award in the EY ... The Entrepreneur Of The Year Program, now in ...
(Date:6/29/2015)... , June 29, 2015   For the seventh ... sciences to assess their overall digital maturity called the ... that these companies are not maturing fast enough. While ... industry in numerous ways overall and customers are increasingly ... terms of digital customer engagement.  ...
(Date:6/26/2015)... MA (PRWEB) , ... June 26, 2015 , ... ... U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded ... to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This ...
Breaking Biology Technology:Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... Cerecor Inc. , a biopharmaceutical company focused on the ... activity is in the human nervous system, announced today ... overallotment of its January 2012 Series A preferred stock ... including members of Cerecor,s Board of Directors , ...
... American researchers have shown that prospective magnetic fusion power ... used for the production of weapon-usable materials than nuclear ... The researchers, from Princeton University, found that if nuclear ... there is little risk of fissile materials being produced ...
... N.Y. Jie Lian, assistant professor in the Department ... Institute, has won a prestigious Faculty Early Career Development ... Lian will use the five-year, $500,000 award to further ... in nuclear energy systems. The CAREER Award is given ...
Cached Biology Technology:Cerecor Raises $22 Million Series A Financing 2Fusion presents low proliferation risk, experts conclude 2Rensselaer professor Jie Lian receives NSF CAREER Award 2
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... December 7, 2012 More than 100 academic ... major world-wide initiative: Mathematics of Planet Earth (MPE) ... made by mathematics in tackling global problems, including ... climate change; sustainability; and pandemics. MPE2013 partners will ...
... plant growth patterns are influenced by a variety of ... roots exhibit characteristic behaviours called ,waving, and ,skewing, which ... plants grown on the International Space Station (ISS) ... published in BioMed Central,s open access journal BMC ...
... a biological adaptation that enables them to thrive in the ... on the trait appears to be linked to different genes ... University scientist and colleagues shows. The adaptation is the ... of hemoglobin, the oxygen-carrying protein in red blood cells. Members ...
Cached Biology News:Mathematicians tackle global issues 2Mathematicians tackle global issues 3What happens to plant growth when you remove gravity? 2Different genes behind same adaptation to thin air 2
... The Neural Stem Cell Expansion Kit - Neurosphere ... neural stem cell expansion as neurospheres in ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
Biology Products: